Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAD603 in healthy volunteers
NCT06200597Phase 1Completed
- Sponsor
- Almirall
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of LAD603 (14 arms), sponsored by Almirall. Primary endpoints: Adverse Events at 64 days, Vital Sign Parameters at 64 days and 2 more. Started Dec 2023; status: completed.
02
Drugs
LAD603
Beyond the preview
Go deeper on NCT06200597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06200597.